Patient-derived tumor organoids (PDTOs) be generated from tissue samples after receiving informed consent. The technology is based on the expansion of primary cells under defined culturing conditions. Efficient protocols have been described for different types of cancer, such as colorectal, pancreatic and stomach cancer. PDTO biobanks recapitulate the molecular and phenotypic properties of the original tumor tissue. At the Georg-Speyer-Haus, we have established a biobank for colorectal cancer PDTOs from clinical samples from more than 250 patients at UCT Frankfurt. Molecular and histopathological analyses show a high degree of similarity to the original tumor tissue. Infrastructures for functional characterization have been established, including a platform for drug testing on PDTOs. As part of the FCI, the Organoid Biobank is open to translational projects, and supports FCI researchers in developing their own PDTO models for different tumor entities. Existing models include tumors from ovarian cancer, brain metastases and head and neck tumors.
Service available to – all entities, including for-profit organizations.
Priority service for – no distinctions.